Further studies to silence and re-express our shortlisted miRs of interest and analyse panels of miRs (42) in additional HER2-positive cell lines might provide valuable information on their role in resistance to trastuzumab-based therapy in HER2-positive oesophago-gastric cancer patients, but this was beyond the scope of this study. This evidence concerns the gene ERBB2 and gastric cancer.